[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer]. 2022

Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
Dept. of Surgery, Breast Surgery, Tokyo Women's Medical University Adachi Medical Center.

CREATE-X trial demonstrated the effectiveness of additional capecitabine therapy in prolonging disease-free survival among patients who are HER2 negative, especially those with triple-negative breast cancer who had residual invasive disease after standard neoadjuvant chemotherapy. We investigated our data regarding adjuvant capecitabine for residual disease. Ten patients were enrolled, and the average age of the patients was 54.2 years. All patients completed 8 courses of treatment; all adverse events were Grade 2 or lower. Five-year disease-free survival rate was 70.0% in an average observation period of 40.9 months. Three patients recurred within 2 years, and all patients had brain metastasis. In the CREATE-X trial, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group; our results were same as those of CREATE-X. Brain metastasis may be detected by the early phase of enhanced brain MRI.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069287 Capecitabine A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER. N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine,Xeloda
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy
D018572 Disease-Free Survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. Survival, Disease-Free,Disease Free Survival,Survival, Disease Free
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
September 2023, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
January 2023, Journal of personalized medicine,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
October 2013, Annals of oncology : official journal of the European Society for Medical Oncology,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
November 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
September 2010, The Journal of surgical research,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
October 2015, Anticancer research,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
July 2022, Expert review of anticancer therapy,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
January 2023, Frontiers in oncology,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
November 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yuko Ishibashi, and Akira Hirano, and Hiroko Yukawa, and Aya Kitano, and Asaka Kodera, and Saki Fujita, and Akinori Hattori, and Mari Kamimura, and Shunichi Shiozawa
July 2018, Breast cancer research and treatment,
Copied contents to your clipboard!